

PHARMACEUTICAL 2023

## Homology Medicines Inc. Rank 82 of 446









RealRate

PHARMACEUTICAL 2023



## Homology Medicines Inc. Rank 82 of 446

The relative strengths and weaknesses of Homology Medicines Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Homology Medicines Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 91% points. The greatest weakness of Homology Medicines Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 216%, being 173% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	181,015
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	22,576
Liabilities, Non-Current	27,916
Other Assets	46,377
Other Compr. Net Income	-397
Other Expenses	715
Other Liabilities	0
Other Net Income	128,991
Other Revenues	3,208
Property and Equipment	1,078
Research and Development	98,351
Selling, General and Administrative Expense	38,138

Output Variable	Value in 1000 USD
Assets	228,470
Liabilities	50,492
Expenses	137,204
Revenues	3,208
Stockholders Equity	177,978
Net Income	-5,005
Comprehensive Net Income	-5,204
Economic Capital Ratio	216%

